We are live on ! Find out more

AstraZeneca

AZN

Market cap $257B

165.98 USD

+1.49

0.91%

At close Updated Aug 21, 4:00 PM EDT

Pre-market

After hours

165.24

-0.74

0.45%

1 day

0.91%

5 days

6.19%

1 month

-1.98%

3 months

-12.53%

6 months

-19.01%

Year to date

-9.37%

1 year

3.14%

5 years

41.14%

10 years

145.17%

About: A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Employees: 96,100

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 35.4%

Neutral 41.5%

Negative 23.2%

Zacks Investment Research

BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment

BMRN's $490M Alesta deal adds ALE1, a potential oral HPP therapy, broadening its rare bone disease portfolio and clinical pipeline.

BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment

AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?

Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling, yet each company's standalone strength deserves closer scrutiny. Overall, AZN and BMY occupy leading positions in the cancer and immune-mediated inflammatory diseases markets. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the rival.

AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?

The Key to Pharma M&A: Never Shopping Hungry

Pharmaceutical chiefs are always hunting for drugs to replace expiring blockbusters. But shopping while hungry can lead to expensive mistakes.

The Key to Pharma M&A: Never Shopping Hungry

Zacks Investment Research

AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success

AstraZeneca halts a phase III NSCLC study for volrustomig after data show that the regimen is unlikely to meet key survival goals, while other lung cancer trials shine.

AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success

Proactive Investors

AstraZeneca maintains Citi 'buy' rating despite mixed pipeline updates

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has retained a 'buy' rating from Citi following a mixed set of pipeline updates, with the broker saying its underlying investment thesis remains unchanged and that the drugmaker continues to offer the strongest growth and pipeline profile in the sector. Citi highlighted positive results from the Phase III SAFFRON trial, where Tagrisso plus Orpathys met the primary endpoint and demonstrated statistically significant and clinically meaningful progression-free survival and overall survival benefits against platinum-doublet chemotherapy in second-line EGFR-mutated, MET-driven non-small cell lung cancer.

AstraZeneca maintains Citi 'buy' rating despite mixed pipeline updates

AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies

AstraZeneca Plc (NYSE:AZN) on Monday reported a mix of clinical trial outcomes for its lung cancer treatments, achieving notable successes in two late-stage trials while discontinuing a third study due to missed primary endpoints.

AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies

TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).

TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

Proactive Investors

AstraZeneca lung cancer drug combination extends survival in trial

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has reported positive results from a late-stage trial of a two-drug combination for a hard-to-treat form of lung cancer, potentially opening the way to approval around the world. The study tested the company's established lung cancer pill Tagrisso alongside a newer drug called Orpathys, developed with the Hong Kong-based biotech HUTCHMED.

AstraZeneca lung cancer drug combination extends survival in trial

AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review

The decision was based on the recommendation of the Independent Data Monitoring Committee, which said volrustomig plus chemotherapy was unlikely to reach primary endpoints.

AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review

AstraZeneca to discontinue late-stage lung cancer trial for volrustomig

AstraZeneca on Monday said it is discontinuing a late stage trial ‌that tested volrustomig plus chemotherapy in patients with metastatic non-small cell lung cancer.

AstraZeneca to discontinue late-stage lung cancer trial for volrustomig

See News Rankings

Price charts implemented using Lightweight Charts™